Antithrombin III is an inhibitor of procoagulation cascade using intrinsic and common pathways, the deficiency of which presents with venous thromboembolisms. A 62-year-old man who had anterior myocardial infarction 6 months ago was admitted to our outpatient clinic. Intracardiac defibrillator (ICD) was also implanted after myocardial infarction for primary protection. He was prescribed with dual antiplatelets on discharge after percutaneous coronary intervention to left anterior descending artery. Transthoracic echocardiography (TTE) revealed decreased ejection fraction (25%), apical thrombus in the left ventricle, giant biatrial thrombi, and thickened ICD lead in the right chambers ( Fig. 1a-d (Fig. 2d , Video 4). ICD lead was observed to be thickened, which was considered secondary to thrombus burden (Fig. 3a, b) . Thrombophilia panel was obtained from the patient's venous blood sample before starting intravenous heparin therapy. Heparin therapy was carried on for a week without stopping. Biochemical tests were normal for factor V Leiden mutation, protein C-S deficiency, prothrombin gene mutation, MTHFR gene mutation, thrombomodulin gene mutation, Antithrombin III deficiency concomitant with atrial fibrillation causes thrombi in all chambers: 2D and 3D echocardiographic evaluation hyperhomocysteinemia, and other rheumatological diseases. Antithrombin III was interestingly detected as 55% of the reference level. Antithrombin concentrates were also initiated after the A3-D diagnosis. After 2 weeks, TEE was repeated, but the giant thrombi persisted; therefore, the option of surgery was offered to the patient. However, the patient refused the operation because of high risk under informed consent , and he was discharged from our hospital under warfarin, ticargrelor, and acetyl-salicyclic acid therapy. 
